Wilson Sonsini Goodrich & Rosati and Morrison & Foerster have scored key advisory roles in the $640 million privatisation of Nasdaq-listed Integrated Silicon Solutions Inc (ISSI) by a consortium of Chinese investors.

The buyer group, led by Summitview Capital, will acquire all of the outstanding shares of ISSI for $19.25 per share in cash. With the closing of the merger, ISSI's operations in Taiwan will either be restructured or sold to comply with Taiwan's laws and regulations.

A Morrison & Foerster team led by Beijing partner Sherry Yin and San Francisco partner Michael O’Bryan is serving as U.S. legal advisor to the buyer. Wilson Sonsini Austin partner Robert Suffoletta and San Francisco partner Robert Ishii are representing ISSI.

ISSI makes integrated circuits for automotive, communications, industrial and digital consumer customers.

The deal, which is expected to close during the third quarter of this year, is subject to approval from ISSI’s investors, as well as antitrust and regulatory approvals.

Related Articles

中伦、君合等牵头香港第二宗18C章上市项目(ZH/EN)

智能汽车芯片公司黑芝麻智能在香港联交所主板成功上市。发行人方面,中伦律师事务所担任中国律师,高伟绅律师事务所担任香港及美国律师,高盖茨律师事务所就美国出口管制法律提供意见;保荐人方面,君合律师事务所担任中国律师,美国威尔逊律师事务所担任香港及美国律师。

中概股接连迎来两宗重大交易,汉坤、凯易等扮演领衔角色(ZH/EN)

过去两周,来自中国湖北武汉的超跑电动车制造商路特斯,以及来自湖南长沙的互联网券商微牛,先后通过SPAC合并交易实现在美国纳斯达克上市。

竞天公诚、方达领衔药明合联香港IPO,创当年度纪录(ZH/EN)

by Mari Iwata |

近日,药明合联于香港交所主板成功上市,成为今年迄今为止在香港的第三大IPO,以及最大医疗健康和生物科技IPO项目。